Evidence map›Paper›PMID 35383922›Full record

ArticleHeadache2022

Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid.

Michel D Ferrari, Karin W M Zuurbier, Steve Barash, Xiaoping Ning, Joshua M Cohen

Open access · hybridAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Headache, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Michel D FerrariLeiden University Medical Centre, Leiden, The Netherlands.
Karin W M ZuurbierTeva Netherlands B.V., Haarlem, The Netherlands.
Steve BarashTeva Branded Pharmaceutical Products R&D, Inc., West Chester, Pennsylvania, USA.
Xiaoping NingTeva Branded Pharmaceutical Products R&D, Inc., West Chester, Pennsylvania, USA.
Joshua M CohenTeva Branded Pharmaceutical Products R&D, Inc., West Chester, Pennsylvania, USA.
Teva Pharmaceuticals (United States) · USLeiden University Medical Center · NLTeva Pharmaceuticals (Netherlands) · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Botulinum Toxins, Type AMigraine DisordersAntibodies, MonoclonalChronic DiseaseDouble-Blind MethodHumansTopiramateTreatment OutcomeValproic AcidAntibodies, MonoclonalBotulinum Toxins, Type AfremanezumabTopiramateValproic Acidchronic migrainefremanezumabonabotulinumtoxinAtopiramatevalproic acid

Identifiers

PMID35383922
PMCPMC9322527
OpenAlexW4224290820

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.